Fungal microbiota in COPD patients during exacerbations

IF 2.2 4区医学 Q3 MYCOLOGY

Journal de mycologie medicale Pub Date : 2025-03-10 DOI:10.1016/j.mycmed.2025.101543

Weronika Gawor , Katarzyna Góralska , Sandra Galant , Sebastian Majewski , Wojciech Piotrowski , Joanna Miłkowska-Dymanowska , Justyna Kiszałkiewicz , Ewa Brzeziańska-Lasota

{"title":"Fungal microbiota in COPD patients during exacerbations","authors":"Weronika Gawor , Katarzyna Góralska , Sandra Galant , Sebastian Majewski , Wojciech Piotrowski , Joanna Miłkowska-Dymanowska , Justyna Kiszałkiewicz , Ewa Brzeziańska-Lasota","doi":"10.1016/j.mycmed.2025.101543","DOIUrl":null,"url":null,"abstract":"<div><div>Acute exacerbations of chronic obstructive pulmonary disease (COPD) results in increased mortality and can be triggered by a range of factors, including microorganisms. Very little studies have examined the role of fungi and fungal diversity in COPD patients. The aim of the study was to determine the role of <em>Candida</em> in COPD during an exacerbation. Oral swabs, sputum, feces and whole blood samples were collected from the AECOPD patients and control group. Mycological and serological analysis were performed. Yeast were statistically significantly more often isolated from the AECOPD group (97.06%) than from the control group (26.32%). 7 species were isolated from the AECOPD, and 3 from the control group. Dominated <em>Candida albicans</em> followed by <em>C. tropicalis</em>. α-diversity was much greater in AECOPD patients than in controls. β-diversity was also assessed. A much higher level of antimycotic resistance was observed in isolates from the AECOPD group, which affects the effectiveness of therapy. Serological tests showed twice the frequency of positive results in the AECOPD group. The mycobiota of AECOPD patients is numerically and taxonomically richer than controls, including species less frequently recorded in humans. Our research confirms that fungal mycobiota may be a potential factor influencing the development of exacerbations and progression of COPD.</div></div>","PeriodicalId":14824,"journal":{"name":"Journal de mycologie medicale","volume":"35 2","pages":"Article 101543"},"PeriodicalIF":2.2000,"publicationDate":"2025-03-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal de mycologie medicale","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1156523325000125","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"MYCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Acute exacerbations of chronic obstructive pulmonary disease (COPD) results in increased mortality and can be triggered by a range of factors, including microorganisms. Very little studies have examined the role of fungi and fungal diversity in COPD patients. The aim of the study was to determine the role of Candida in COPD during an exacerbation. Oral swabs, sputum, feces and whole blood samples were collected from the AECOPD patients and control group. Mycological and serological analysis were performed. Yeast were statistically significantly more often isolated from the AECOPD group (97.06%) than from the control group (26.32%). 7 species were isolated from the AECOPD, and 3 from the control group. Dominated Candida albicans followed by C. tropicalis. α-diversity was much greater in AECOPD patients than in controls. β-diversity was also assessed. A much higher level of antimycotic resistance was observed in isolates from the AECOPD group, which affects the effectiveness of therapy. Serological tests showed twice the frequency of positive results in the AECOPD group. The mycobiota of AECOPD patients is numerically and taxonomically richer than controls, including species less frequently recorded in humans. Our research confirms that fungal mycobiota may be a potential factor influencing the development of exacerbations and progression of COPD.

查看原文本刊更多论文

慢性阻塞性肺病患者加重期的真菌微生物群

慢性阻塞性肺疾病（COPD）的急性加重可导致死亡率增加，并可由包括微生物在内的一系列因素引发。很少有研究检查真菌和真菌多样性在COPD患者中的作用。该研究的目的是确定念珠菌在COPD加重期间的作用。收集AECOPD患者和对照组的口腔拭子、痰、粪便和全血样本。进行真菌学和血清学分析。AECOPD组酵母菌分离率（97.06%）显著高于对照组（26.32%）。从AECOPD中分离到7种，从对照组中分离到3种。以白色念珠菌为主，其次为热带念珠菌。α-多样性在AECOPD患者中明显高于对照组。还对β-多样性进行了评估。在AECOPD组分离株中观察到更高水平的抗真菌耐药性，这影响了治疗的有效性。血清学测试显示AECOPD组阳性结果的频率是前者的两倍。AECOPD患者的真菌群在数量和分类上都比对照组丰富，包括在人类中较少记录的物种。我们的研究证实，真菌菌群可能是影响COPD恶化和进展的潜在因素。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal de mycologie medicale 医学-真菌学

CiteScore

5.10

自引率

2.80%

发文量

审稿时长

6-12 weeks

期刊介绍： The Journal de Mycologie Medicale / Journal of Medical Mycology (JMM) publishes in English works dealing with human and animal mycology. The subjects treated are focused in particular on clinical, diagnostic, epidemiological, immunological, medical, pathological, preventive or therapeutic aspects of mycoses. Also covered are basic aspects linked primarily with morphology (electronic and photonic microscopy), physiology, biochemistry, cellular and molecular biology, immunochemistry, genetics, taxonomy or phylogeny of pathogenic or opportunistic fungi and actinomycetes in humans or animals. Studies of natural products showing inhibitory activity against pathogenic fungi cannot be considered without chemical characterization and identification of the compounds responsible for the inhibitory activity. JMM publishes (guest) editorials, original articles, reviews (and minireviews), case reports, technical notes, letters to the editor and information. Only clinical cases with real originality (new species, new clinical present action, new geographical localization, etc.), and fully documented (identification methods, results, etc.), will be considered. Under no circumstances does the journal guarantee publication before the editorial board makes its final decision. The journal is indexed in the main international databases and is accessible worldwide through the ScienceDirect and ClinicalKey platforms.